Table 1.
Baseline characteristics and outcomes of patients stratified by anticoagulation treatment status prior to the stroke.
| Anticoagulation at time of index stroke (n = 546) | No anticoagulation prior to index stroke (n = 972) | |
|---|---|---|
| Age (median, interquartile range) | 77 (68 – 84) | 78 (69 – 86) |
| Sex (% men) | 51.6% (282) | 48.9% (475) |
| Hypertension (%) | 84.4% (461) | 81.8% (95) |
| Diabetes (%) | 39.7% (217) | 30.2% (293/971) |
| Hyperlipidemia (%) | 59.9% (327) | 54.0% (525) |
| Prior Stroke or TIA (%) | 39.6% (216) | 26.8% (260) |
| Congestive Heart Failure (%) | 29.7% (159/535) | 22.1% (212/961) |
| Coronary Artery Disease (%) | 38.1% (208) | 27.5% (267) |
| CHADS2 Vasc score (median, interquartile range) | 5 (4 – 6) | 4 (3 – 6) |
| CHADS2Vasc 0–1 (%) | 3.8% (21) | 6.0% (58) |
| Antiplatelet use (%) | 32.1% (175) | 58.8% (572) |
| Statin use (%) | 64.7% (353) | 49.5% (481) |
| Ipsilateral atherosclerosis ≥ 50% (%) | 18.0% (97/538) | 15.5% (148/954) |
| Ischemic lesion size > 10 mL (%) | 57.0% (286/502) | 60.0% (540/900) |
| NIHSS score (median, interquartile range) | 6 (2 – 14) | 9 (3 – 16) |
| Ejection fraction (median, interquartile range) | 55 (50 – 65) | 60 (50 – 65) |
| Severe left atrial enlargement (%) | 43.9% (189/431) | 34.9% (279/800) |
| Alteplase treatment (%) | 14.7% (80) | 36.7% (357) |
| Mechanical thrombectomy (%) | 22.5% (123) | 26.7% (261) |
| Anticoagulation not initiated within 90 days (%) | 4.4% (24) | 19.6% (192) |
| Symptomatic intracranial hemorrhage at 90 days (%) | 1.6% (9) | 1.3% (13) |
| Recurrent ischemic event at 90 days (%) | 8.1% (44) | 6.2% (60/972) |